Needham & Company LLC Raises Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00

Trevi Therapeutics (NASDAQ:TRVI) had its price target boosted by stock analysts at Needham & Company LLC from $22.00 to $24.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 124.30% from the stock’s current price.

TRVI has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. Stifel Nicolaus boosted their target price on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. Leerink Partners upped their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.60.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $10.70 on Wednesday. The company has a 50-day simple moving average of $11.14 and a two-hundred day simple moving average of $10.93. The firm has a market capitalization of $1.37 billion, a PE ratio of -33.44 and a beta of 0.94. Trevi Therapeutics has a one year low of $4.85 and a one year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. Analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Hilton Head Capital Partners LLC bought a new position in shares of Trevi Therapeutics during the fourth quarter valued at $40,000. Caitong International Asset Management Co. Ltd bought a new position in Trevi Therapeutics in the 4th quarter worth about $50,000. Russell Investments Group Ltd. grew its position in Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Trevi Therapeutics by 32.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares during the last quarter. Finally, BIT Capital GmbH increased its stake in Trevi Therapeutics by 32.0% during the 3rd quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock valued at $62,000 after purchasing an additional 1,633 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Key Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Company says it achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and regulatory de‑risking milestone that can drive long‑term value if trials and endpoints are favorable. Article Title
• Positive Sentiment: Q4 2025 results topped expectations — EPS of ($0.06) vs. consensus ~($0.0966). The beat and management commentary from the earnings call support near‑term credibility on execution. Earnings Transcript
• Positive Sentiment: Broker support remains strong: Needham raised its target to $24 (Buy) and HC Wainwright reiterated a Buy with a $21 target and updated EPS forecasts — analyst backing increases visibility for upside expectations. Broker Note HC Wainwright Details
• Positive Sentiment: D. Boral Capital reaffirmed a Buy and $19 target, adding to the cluster of buy ratings—positive for investor sentiment and analyst coverage breadth. Article Title
• Neutral Sentiment: Morgan Stanley lowered its price target from $19 to $18 but kept an Overweight rating — still positive sentimentually, but the cut trims some near‑term upside expectations. Article Title
• Negative Sentiment: JonesTrading trimmed its target from $25 to $24 (remains a Buy) — a modest downward adjustment in analyst upside that slightly cools the market’s price‑target momentum. Article Title

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.